Form 8-K · Current report
Insulet Corporation 8-K, filed Aug 5, 2026
- Filed
- CIK
- 0001145197
- Accession no.
- 0001145197-26-000167
Summary
Insulet reported second-quarter 2026 revenue of $801.7 million, up 23.5% year over year (22.7% in constant currency), net income of $95.0 million, or $1.37 per diluted share, and adjusted EPS of $1.66. CEO Ashley McEvoy said the quarter reflected broad-based growth and margin expansion while the company updated its full-year 2026 total revenue growth guidance to 20%–22% in constant currency from 21%–23% to reflect what it is learning as it scales in type 2 diabetes.
Key points
- Total Omnipod revenue was $795.9 million, up 24.6%; U.S. Omnipod revenue rose 20.1% to $544.1 million, and international Omnipod revenue rose 35.5% to $251.8 million.
- Second-quarter revenue exceeded the high end of Insulet's constant-currency guidance range of 20%–22%, and third-quarter 2026 total revenue growth guidance is 17.5%–19.5%.
- Insulet launched Omnipod 5 and Omnipod Discover in Spain, its 26th country for Omnipod and 20th for Omnipod 5, and expanded Omnipod 5 compatibility with Abbott's FreeStyle Libre 3 Plus.
- At the American Diabetes Association 2026 Scientific Sessions, Insulet presented STRIVE results supporting Omnipod 6 and the EVOLUTION 3 feasibility study of fully closed-loop technology for type 2 diabetes.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02. Results of Operations and Financial Condition. On August 5, 2026, Insulet Corporation (the “Company”) announced its financial results for the second quarter ended June 30, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.